To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue
Clinical trial NCT04593758 · COMPLETED
Trial details
- NCT number
- NCT04593758
- Sponsor
- Cornerstone Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-01
- Primary completion
- 2023-03-09
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.